Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations
- Written by ACN Newswire
Paris, France and Cambridge, Massachusetts, USA, Oct 4, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as...